

Naval Medical Research Institute  
503 Robert Grant Avenue  
Silver Spring, Maryland 20910-7500



NMRC 2004-001 September 2004

---

## **MELATONIN DOES NOT PROVIDE PROTECTION AGAINST HYPERBARIC OXYGEN (HBO) INDUCED SEIZURES**

**M.J. Swiergosz  
D.O. Keyser  
W. Koller**

**Bureau of Medicine and Surgery  
Department of the Navy  
Washington, DC 20372-5120**

**20060417021**

**Approved for public release;  
Distribution is unlimited**

**Naval Medical Research Institute  
503 Robert Grant Avenue  
Silver Spring, Maryland 20910-7500**



**NMRC 2004-001 September 2004**

---

---

**MELATONIN DOES NOT PROVIDE PROTECTION AGAINST  
HYPERBARIC OXYGEN (HBO) INDUCED SEIZURES**

**M.J. Swiergosz  
D.O. Keyser  
W. Koller**

**Bureau of Medicine and Surgery  
Department of the Navy  
Washington, DC 20372-5120**

**Approved for public release;  
Distribution is unlimited**

## NOTICES

The opinions and assertions contained herein are the private ones of the writer and are not to be construed as official or reflecting the views of the naval service at large.

When U.S. Government drawings, specifications, and other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever. The fact that the Government may have formulated, furnished or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

Additional copies may be purchased from:

Office of the Under Secretary of Defense (Acquisition & Technology)  
Defense Technical Information Center  
8725 John J. Kingman Road, Suite 0944  
Ft. Belvoir, VA 22060-6218

Federal Government agencies and their contractors registered with the Defense Technical Information Center should direct requests for copies of this report to:

TECHNICAL REVIEW AND APPROVAL  
NMRC 2004-001

The experiments reported herein were conducted according to the principles set forth in the current edition of the "Guide for the Care and Use of Laboratory Animals," Institute of Laboratory Animals Resources, National Research Council.

This technical report has been reviewed by the NMRC scientific and public affairs staff and is approved for publication. It is releasable to the National Technical Information Service where it will be available to the general public, including foreign nations.

RICHARD B. OBERST  
CAPT, MSC, USN  
Commanding Officer  
Naval Medical Research Center

**REPORT DOCUMENTATION PAGE**

Form Approved  
OMB No. 0704-01-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden to Department of Defense, Washington Headquarters Services Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

**PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> September 2004		<b>2. REPORT TYPE</b> Technical Report		<b>3. DATES COVERED (From - To)</b> 1999-2001	
<b>4. TITLE AND SUBTITLE</b> Melatonin does not provide protection against hyperbaric oxygen (HBO) induced seizures				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b>	
				<b>5c. PROGRAM ELEMENT NUMBER</b> 62233N	
<b>6. AUTHORS</b> Matthew J. Swiergosz, David O. Keyser, Wayne A. Koller				<b>5d. PROJECT NUMBER</b> 333	
				<b>5e. TASK NUMBER</b> .127	
				<b>5f. WORK UNIT NUMBER</b> A0018	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Naval Medical Research Center (Code 00) 503 Robert Grant Ave. Silver Spring, Maryland 20910-7500				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b> 2004-001	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Bureau of Medicine and Surgery (Med-02) 2300 E. Street, N.W. Washington, DC 20372-5300				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b> BUMED	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b> DN241126	
<b>12. DISTRIBUTION/AVAILABILITY STATEMENT</b> Approved for public release, distribution unlimited.					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  Acute exposure to hyperbaric oxygen (HBO) can result in toxicity to the central nervous system (CNS). The most onerous manifestation of CNS oxygen toxicity is the onset of generalized tonic-clonic seizures. HBO-induced convulsions are of particular importance to the Navy, as it is a limiting factor in the duration of diving missions involving surface supplied oxygen and use of the LAR V and MK-15/16 closed-circuit SCUBA apparatus, and the application of HBO medical treatment for decompression sickness. The causal mechanism of HBO-induced seizures is presently unknown. Melatonin has not been tested in its capacity as an anticonvulsant in HBO conditions likely to produce seizures (6 atmospheres absolute). The goal of this research was to examine melatonin prophylaxis in HBO conditions that reliably produce CNS toxicity.					
<b>15. SUBJECT TERMS</b> diving, oxygen-induced seizures, oxygen toxicity, hyperbaric oxygen					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			Diana Temple
Unclass	Unclass	Unclass	Unclass	13	<b>19B. TELEPHONE NUMBER (Include area code)</b> 301.319.7642

## TABLE OF CONTENTS

INTRODUCTION .....	3
EXPERIMENT 1 .....	4
METHODS .....	5
Animals and Injectants.....	5
HBO Exposure .....	5
Behavior Observation .....	5
RESULTS .....	6
EXPERIMENT 2 .....	6
METHODS .....	7
Animals and Injectants.....	7
HBO Exposure and Behavior Observation .....	7
RESULTS .....	7
CONCLUSIONS.....	8
RECOMMENDATIONS .....	8
ACKNOWLEDGEMENTS.....	9
REFERENCES .....	10
APPENDIX A: DATA SHEET .....	12
APPENDIX B: EXAMPLE OF TEXT DATA FILE .....	13

## INTRODUCTION

Acute exposure to hyperbaric oxygen (HBO) can result in toxicity to the central nervous system (CNS)(1). The most onerous manifestation of CNS oxygen toxicity is the onset of generalized tonic-clonic seizures. HBO-induced convulsions are of particular importance to the Navy, as it is a limiting factor in the duration of diving missions involving surface supplied oxygen and use of the LAR V and MK-15/16 closed-circuit SCUBA apparatus, and the application of HBO medical treatment for decompression sickness (2).

The causal mechanism of HBO-induced seizures is presently unknown. CNS dysfunction as a result of increased exposure to HBO might be related to the deleterious effects of elevated oxygen free radical production (1). The primary utilization of O<sub>2</sub> in the central nervous system occurs during the oxidation of carbohydrates involved in the generation of adenosine triphosphate. Residual O<sub>2</sub> in the brain is reduced to reactive oxygen species assumed to be neutralized by endogenous antioxidative compounds (e.g., glutathione system, superoxide dismutase, and catalase). Endogenous defense mechanisms may be overwhelmed in a HBO environment where the production of oxygen free radicals exceeds normal levels (3-6).

The pineal hormone, melatonin (N-acetyl-5-methoxy-tryptamine) is easily taken up in the brain and is considered to be a potent free radical scavenger (4, 7-12). Melatonin has also exhibited anticonvulsive properties in various seizure models. The severity of pentylenetetrazol-induced convulsions was reduced in gerbils receiving daily subcutaneous doses of melatonin (13, 14). Incidence of potassium cyanide-induced convulsions was reduced in mice given subcutaneous melatonin (12). Kainate-induced convulsions were reduced in rats given intraperitoneal melatonin (15). The occurrence of iron-induced epileptic EEG discharges was reduced in rats given intraperitoneal melatonin (16). Dose-dependent anticonvulsive effects of

melatonin were observed in convulsions induced by intracerebroventricular administration of quinolinic acid, kainate, glutamate, NMDA, and pentylenetetrazole (17). However, in most of the aforementioned seizure models, melatonin did not eradicate convulsions. Lapin, et al. (17) reported longer seizure latencies or suppression of seizures as a function of melatonin administration.

Melatonin has not been tested in its capacity as an anticonvulsant in HBO conditions likely to produce seizures (6 atmospheres absolute (ATA)). The goal of this research was to examine melatonin prophylaxis in HBO conditions that reliably produce CNS toxicity.

## **EXPERIMENT 1**

The rationale for using 6 ATA as a dive depth for these experiments was to minimize time to seizure, minimize the onset of pulmonary toxicity as a complicating factor, and to see if extreme dive profiles are affected by interventions.

Melatonin is more prominently known for its involvement in circadian rhythms and sleep (18). These potential "side-effects" could be equally as harmful in a combat diver scenario, thus we initially sought to test a low dose that might produce prophylaxis in our HBO seizure model. Pablos, et al. (4), reported a reduction in oxidative stress and elevated production of endogenous antioxidant defenses in brain tissues of rats given 10 mg/kg intraperitoneal melatonin prior to 90 minutes of 4 ATA HBO exposure.

We designed our experiment based upon the assumption that the mean seizure latency in control conditions would be approximately 20 min with a standard deviation of 15 min. We sought to detect a difference between control and treatment conditions when the mean seizure latency of the treatment (i.e., melatonin) was at least 45 min. The rationale for seeking a

treatment effect of this size was that it would be operationally important and, assuming depth dependency of any intervention, this time would increase for shallower dives. Our parameters required relatively small sample sizes ( $n \geq 7$ ) to produce power estimates  $\geq .80$  when alpha was set at .05 (19, 20).

## **METHODS**

### ***Animals and Injectants***

Twenty-four, male Sprague-Dawley rats (mean = 330 g, SD = 39.96 g, Charles River) were randomly assigned to one of three experimental conditions; saline (control), 10% dimethylsulfoxide (Sigma D-8779) in saline (DMSO+saline), or 10 mg/kg melatonin (Sigma M-5250) + 10% dimethylsulfoxide-saline (MEL10). Solutions were prepared a few minutes prior to intraperitoneal administration, immediately before HBO exposure.

### ***HBO Exposure***

Animals were individually exposed to HBO. The animal was housed in a 28 x 18 x 13 cm Plexiglas cage with air holes and immediately sealed inside a small hyperbaric chamber (approximately 167 liters). After a 90 s flushing period, 100% oxygen was introduced to the chamber at a rate equivalent to 1 foot of sea water (fsw)/s until reaching 165 fsw (6 ATA). Pressure was maintained at  $165 \pm 1$  fsw for behavioral observation until positive identification of a seizure or pulmonary distress, then the chamber was depressurized at 1 fsw/s and the animal was euthanized.

### ***Behavior Observation***

A video camera mounted against a porthole of the hyperbaric chamber provided a clear view of the Plexiglas cage via an external monitor. The primary objective of behavior observation was to identify seizure onset time. The following hallmarks were noted throughout

the dive: facial clonus, forelimb clonus, tonic hindlimb extension, generalized tonic-clonic seizure, and running fits. Pulmonary distress (dyspnea, gagging) was identified and used as an ethical guide to terminate HBO exposure. Animals were observed at all times while in the chamber. The seizure duration of  $\geq 20$  s was selected to ensure positive identification of seizure activity. A list of behavior codes was used as a guide to identify all animal activity during observation (Appendix A). Two dedicated observers verified each other's behavior identification in the animal, and each dive was recorded on videotape for further verification of seizure onset times.

## RESULTS

The difference between onset time of a seizure and the time at which the rat reached 6 ATA was calculated to measure seizure latency to the nearest minute. No animals were surfaced for pulmonary reasons. Mean seizure latencies were calculated for each treatment; control (25.0, SD 15.7 min), DMSO-saline (20.4, SD 14.6 min), and MEL10 (25.4, SD 10.0 min). Statistical analysis revealed no significant differences among treatment pairs (DMSO+saline vs. control,  $t(14) = -.61, p > .05$ ; MEL10 vs. control,  $t(14) = .06, p > .05$ ; MEL10 vs. DMSO+saline,  $t(14) = -.80, p > .05$ ).

## EXPERIMENT 2

Although 10mg/kg of melatonin reduced oxidative stress and produced a significant increase in brain tissue antioxidants after 90 min of HBO exposure at 4 ATA (4), this dose may not have been sufficient to produce a protective effect in the current CNS toxicity model. Using a quinolinate seizure model in mice, Lapin, et al., (17) observed significantly longer seizure latencies with 25, 50 and 100 mg/kg intraperitoneal administration of melatonin compared to the

control vehicle. Thus we tested higher doses of melatonin in our HBO model, one that represented the higher range (75 mg/kg), and a second dose beyond the range (150 mg/kg), employed by Lapin, et al. (17). Given that we observed no differences in seizure latency between the control and DMSO+saline conditions in Experiment 1, we only used DMSO+saline as the control in Experiment 2.

## **METHODS**

### ***Animals and Injectants***

Thirty, male Sprague-Dawley rats (mean = 350 g, SD = 21.84 g, Charles River) were randomly assigned to one of three experimental conditions; 10% dimethylsulfoxide in saline (DMSO+saline), 75 mg/kg melatonin + 10% dimethylsulfoxide-saline (MEL75), or 150 mg/kg melatonin + 10% dimethylsulfoxide-saline (MEL150). As in Experiment 1, solutions were prepared a few minutes prior to administration and animals were given an intraperitoneal injection immediately before HBO exposure.

### ***HBO Exposure and Behavior Observation***

HBO exposure and behavior observation were the same as Experiment 1. In this case, however, behavioral data were recorded electronically and later transferred to text for off-line analysis (see Appendix B for example text file).

## **RESULTS**

The difference between seizure onset time and the time at which the animal reached 6 ATA was calculated to measure seizure latency to the nearest minute. Mean seizure latencies were calculated for each treatment; DMSO+saline (37.1, SD = 22.5), MEL75 (33.5, SD = 19.0),

and MEL150 (25.5, SD = 11.3). Two animals were surfaced for pulmonary reasons, one in the DMSO+saline group (latency = 84 min), and one in the MEL75 group (latency = 79 min). These animals elevated their respective treatment mean and standard deviation, but had no bearing on the final statistical outcome. There were no significant differences among treatment pairs (MEL75 vs. DMSO+saline,  $t(18) = -.39, p > .05$ ; MEL150 vs. DMSO+saline,  $t(18) = -1.46, p > .05$ ; MEL150 vs. MEL75,  $t(18) = -.114, p > .05$ ).

### CONCLUSIONS

These results suggest that melatonin pretreatment at the dosages used provides no benefit against the occurrence of HBO-induced seizure. We did not observe any effect of intraperitoneal administration of melatonin on HBO-induced seizure latency. Melatonin doses employed here (10, 75 and 150 mg/kg) were comparable to doses producing prophylactic effects in other animal seizure models. Although statistical power was less than anticipated in Experiment 2 given the longer mean seizure latency in the control condition (DMSO+saline) and slightly elevated standard deviations, mean seizure latencies in all of the melatonin conditions were not different from anticipated latencies with no intervention.

Perhaps the severity of this profile (6 ATA HBO) overwhelmed assumed antioxidant defenses of melatonin. Previous research on melatonin's capacity to reduce oxidative stress was conducted under less toxic conditions (4 ATA HBO)(4). It is unclear whether melatonin would limit CNS O<sub>2</sub> toxicity in a less severe hyperbaric environment.

### RECOMMENDATIONS

1. Application of melatonin to prolong or eradicate the onset of HBO toxicity (seizures) in human diving investigations is not recommended at this time.

2. Further nonhuman animal research on the prophylactic capability of melatonin in an acute HBO environment is not recommended at this time. However, additional studies could be conducted at NMRC with intracerebroventricular administration to elucidate how this method produced the most dramatic anticonvulsant effects of melatonin in other seizure models (17).

### **ACKNOWLEDGEMENTS**

This research was supported by the Office of Naval Research Work Unit #62233N.333.127.A0018. All procedures were in accordance with the guidelines on laboratory animal use published by the National Research Council. Prior to the experiment, the AALAC accredited Institutional Animal Care and Use Committee reviewed and approved this protocol. The opinions expressed here are those of the authors and do not reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. Government.

## REFERENCES

1. Clark, J. M., & Thom, S. R. (2003). Oxygen under pressure. In G. Bennet & E. Elliot (Eds.), *Bennett and Elliott's physiology and medicine of diving* (5th ed., pp. 358-418). Edinburgh: Saunders.
2. Naval Sea Systems Command, U.S. Navy Diving Manual, NAVSEA SS521-AG-PRO-010, Vol. #5, Rev. 4.
3. Chavko, M., & Harabin, A. L. (1996). Regional Lipid peroxidation in the rat brain after hyperbaric oxygen exposure. *Free Radical Biology & Medicine*, 20, 973-978.
4. Pablos, M. I., Reiter, R. J., Chuang, J., Ortiz, G. G., Guerrero, J. M., Sewerynek, E., Agapito, M. T., Mechiorri, D., Lawrence, R., & Deneke, S. M. (1997). Acutely administered melatonin reduces oxidative damage in lung and brain induced by hyperbaric oxygen. *Journal of Applied Physiology*, 83, 354-358.
5. Stogner, S. W., & Payne, D. K. (1992). Oxygen toxicity. *Annals of Pharmacotherapy*, 26, 1554-1562.
6. Torbati, D., Church, D. F., Keller, J. M., & Pryor, W. A. (1992). Free radical generation in the brain precedes hyperbaric oxygen-induced seizures. *Free Radical Biology & Medicine*, 13, 101-106.
7. Marshall, K., Reiter, R. J., Poeggeler, B., Aruoma, O. I., & Halliwell, B. (1996). Evaluation of the antioxidant activity of melatonin in vitro. *Free Radical Biology & Medicine*, 21, 307-315.
8. Reiter, R. J. (1995). Oxidative processes and antioxidative defense mechanisms in the aging brain. *Federation of American Societies for Experimental Biology Journal*, 9, 526-533.
9. Reiter, R. J. (1996). Functional aspects of the pineal hormone melatonin in combating cell and tissue damage induced by free radicals. *European Journal of Endocrinology*, 134, 412-420.
10. Reiter, R. J., Carneiro, R. C., & Oh, C. (1997). Melatonin in relation to cellular antioxidative defense mechanisms. *Journal of Hormone and Metabolism Research*, 29, 363-372.
11. Reiter, R. J., Tang, L., Garcia, J. J., & Munoz-Hoyos, A. (1997). Pharmacological actions of melatonin in oxygen free radical pathophysiology. *Life Sciences*, 60, 2255-2271.
12. Yamamoto, H., & Tang, H. (1996). Antagonistic effect of melatonin against cyanide-induced seizures and acute lethality in mice. *Toxicology Letters*, 87, 19-24.
13. Champney, T. H., & Champney, J. C. (1992). Novel anticonvulsant action of melatonin in gerbils. *Neuroreport*, 3, 1152-1154.

14. Champney, T. H., & Champney, J. C. (1992). Acute and chronic effects of melatonin as an anticonvulsant in male gerbils. *Journal of Pineal Research*, 20, 79-83.
15. Giusti, P., Lipatiti, M., Franceschini, D., Schiavo, N., Floreani, M., & Manev, H. (1996). Neuroprotection by melatonin from kainite-induced excitotoxicity in rats. *Federation of American Societies for Experimental Biology Journal*, 10, 891-896.
16. Kabuto, H., Yokoi, I., & Ogawa, N. (1998). Melatonin inhibits iron-induced epileptic discharges in rats by suppressing peroxidation. *Epilepsia*, 39, 237-243.
17. Lapin, I. P., Mirzaev, S. M., Ryzov, I. V., & Oxenkrug, G. F. (1998). Anticonvulsant activity of melatonin against seizures induced by quinolinate, kainite, glutamate, NMDA, and pentylentetrazole in mice. *Journal of Pineal Research*, 24, 215-218.
18. Dollins, A. B., Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., & Deng, M. H. (1994). Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. *Proceedings of the National Academy of Sciences*, 91, 1824-1828.
19. Erdfelder, E., Faul, F., & Buchner, A. (1996). GPOWER: A general power analysis program. *Behavior Research Methods, Instruments, & Computers*, 28, 1-11.
20. Keppel, G. (1991) *Design and analysis: A researcher's handbook*. New York: Prentice Hall.



## APPENDIX B: EXAMPLE OF TEXT DATA FILE

Annotations in brackets are provided to clarify code scheme and were not part of the original data file.

MEL47 365g Friday, March 17, 2000

11:21:51 AM 75 mg/kg melatonin + DMSO IP

11:26:12 AM SF [start flush]

11:27:42 AM LS [leave surface]

11:31:10 AM RB 6 ATA 100% O2 [reach bottom]

11:31:18 AM Q [quiet—no noteworthy activity or end of previously noted activity]

11:33:02 AM head movement

11:33:26 AM change position

11:34:21 AM lethargic head movement

11:34:37 AM change position

11:34:53 AM brief SN [sniffing]

11:35:06 AM change position

11:35:25 AM change position

11:37:37 AM occasionally moves head, eyes open, head elevated, calm

11:38:49 AM change position

11:39:03 AM change position

11:40:16 AM occasional head movement

11:47:43 AM change position

11:48:47 AM periodic head movement

11:49:10 AM brief SN

11:49:22 AM change position

11:49:25 AM sniffing

11:49:48 AM Q

11:50:02 AM change position

11:50:15 AM sniffing

11:50:26 AM exploring cage

11:50:54 AM Q

11:51:09 AM jerk

11:51:19 AM twitching

11:52:59 AM jerk

11:53:25 AM jerk

11:53:56 AM jerk

11:54:14 AM jerk

11:54:34 AM jerk

11:55:29 AM sniffing

11:55:38 AM change position

11:55:42 AM jerk

11:55:49 AM jerk

11:55:51 AM jerk

11:56:00 AM facial clonus [onset of first hallmark behavior]

11:56:07 AM forelimb clonus

11:56:13 AM ear flicks

11:56:33 AM Q [end of hallmark behaviors greater than 20 s duration, ∴ seizure latency = 25 min]

11:57:02 AM end observation

11:57:05 AM LB [leave bottom]

11:58:10 AM RS [reach surface]